Medpace Holdings [MEDP] vs Danaher [DHR] Detailed Stock Comparison
Medpace Holdings
NASDAQ
Loading...
Danaher
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Medpace Holdings wins in 11 metrics, Danaher wins in 8 metrics, with 0 ties. Medpace Holdings appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Medpace Holdings | Danaher | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 34.23 | 44.88 | Medpace Holdings |
| Price-to-Book Ratio | 74.89 | 2.89 | Danaher |
| Debt-to-Equity Ratio | 86.93 | 35.45 | Danaher |
| PEG Ratio | 3.15 | -1.20 | Danaher |
| EV/EBITDA | 25.60 | 22.16 | Danaher |
| Profit Margin (TTM) | 18.74% | 14.21% | Medpace Holdings |
| Operating Margin (TTM) | 20.94% | 20.12% | Medpace Holdings |
| EBITDA Margin (TTM) | 20.94% | 20.12% | Medpace Holdings |
| Return on Equity | 89.39% | 6.68% | Medpace Holdings |
| Return on Assets (TTM) | 17.09% | 4.01% | Medpace Holdings |
| Free Cash Flow (TTM) | $572.27M | $5.30B | Danaher |
| 1-Year Return | 15.97% | -24.34% | Medpace Holdings |
| Price-to-Sales Ratio (TTM) | 5.80 | 6.29 | Medpace Holdings |
| Enterprise Value | $12.97B | $166.64B | Danaher |
| EV/Revenue Ratio | 5.81 | 6.94 | Medpace Holdings |
| Gross Profit Margin (TTM) | 29.84% | 59.35% | Danaher |
| Revenue per Share (TTM) | $74 | $33 | Medpace Holdings |
| Earnings per Share (Diluted) | $13.46 | $4.70 | Medpace Holdings |
| Beta (Stock Volatility) | 1.43 | 0.76 | Danaher |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Medpace Holdings vs Danaher Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Medpace Holdings | 2.27% | -1.16% | 46.77% | 53.27% | 33.25% | 35.43% |
| Danaher | 3.87% | -3.01% | 8.42% | 9.15% | -3.01% | -11.27% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Medpace Holdings | 15.97% | 185.19% | 254.59% | 1,516.76% | 1,516.76% | 1,516.76% |
| Danaher | -24.34% | -17.95% | 11.85% | 244.48% | 725.84% | 1,045.51% |
Performance & Financial Health Analysis: Medpace Holdings vs Danaher
| Metric | MEDP | DHR |
|---|---|---|
| Market Information | ||
| Market Cap | $12.94B | $151.04B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 335,247 | 3,241,650 |
| 90 Day Avg. Volume | 619,359 | 4,189,007 |
| Last Close | $463.62 | $211.80 |
| 52 Week Range | $250.05 - $501.30 | $171.00 - $279.90 |
| % from 52W High | -7.52% | -24.33% |
| All-Time High | $501.30 (Jul 22, 2025) | $296.06 (Sep 06, 2021) |
| % from All-Time High | -7.52% | -28.46% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.14% | 0.03% |
| Quarterly Earnings Growth | 0.02% | -0.39% |
| Financial Health | ||
| Profit Margin (TTM) | 0.19% | 0.14% |
| Operating Margin (TTM) | 0.21% | 0.20% |
| Return on Equity (TTM) | 0.89% | 0.07% |
| Debt to Equity (MRQ) | 86.93 | 35.45 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $6.15 | $73.10 |
| Cash per Share (MRQ) | $1.65 | $4.13 |
| Operating Cash Flow (TTM) | $614.10M | $6.17B |
| Levered Free Cash Flow (TTM) | $445.14M | $3.88B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Medpace Holdings vs Danaher
| Metric | MEDP | DHR |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 34.23 | 44.88 |
| Forward P/E | 36.88 | 25.17 |
| PEG Ratio | 3.15 | -1.20 |
| Price to Sales (TTM) | 5.80 | 6.29 |
| Price to Book (MRQ) | 74.89 | 2.89 |
| Market Capitalization | ||
| Market Capitalization | $12.94B | $151.04B |
| Enterprise Value | $12.97B | $166.64B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 5.81 | 6.94 |
| Enterprise to EBITDA | 25.60 | 22.16 |
| Risk & Other Metrics | ||
| Beta | 1.43 | 0.76 |
| Book Value per Share (MRQ) | $6.15 | $73.10 |
Financial Statements Comparison: Medpace Holdings vs Danaher
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | MEDP | DHR |
|---|---|---|
| Revenue/Sales | $558.57M | $5.74B |
| Cost of Goods Sold | $380.22M | $2.23B |
| Gross Profit | $178.35M | $3.51B |
| Research & Development | N/A | $379.00M |
| Operating Income (EBIT) | $113.52M | $1.27B |
| EBITDA | $120.45M | $1.87B |
| Pre-Tax Income | $118.17M | $1.13B |
| Income Tax | $3.58M | $175.00M |
| Net Income (Profit) | $114.60M | $954.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | MEDP | DHR |
|---|---|---|
| Cash & Equivalents | $441.44M | $1.99B |
| Total Current Assets | $821.44M | $9.53B |
| Total Current Liabilities | $1.12B | $6.65B |
| Long-Term Debt | $126.66M | $15.98B |
| Total Shareholders Equity | $593.61M | $50.86B |
| Retained Earnings | $-269.72M | $44.91B |
| Property, Plant & Equipment | $258.19M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | MEDP | DHR |
|---|---|---|
| Operating Cash Flow | $166.55M | $1.47B |
| Capital Expenditures | $-9.99M | $-239.00M |
| Free Cash Flow | $115.84M | $1.05B |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | $-371.90M | $-1.08B |
Short Interest & Institutional Ownership Analysis
| Metric | MEDP | DHR |
|---|---|---|
| Shares Short | 2.50M | 8.45M |
| Short Ratio | 3.60 | 1.93 |
| Short % of Float | 0.11% | 0.01% |
| Average Daily Volume (10 Day) | 335,247 | 3,241,650 |
| Average Daily Volume (90 Day) | 619,359 | 4,189,007 |
| Shares Outstanding | 30.63M | 719.10M |
| Float Shares | 22.22M | 637.13M |
| % Held by Insiders | 0.21% | 0.11% |
| % Held by Institutions | 0.96% | 0.83% |
Dividend Analysis & Yield Comparison: Medpace Holdings vs Danaher
| Metric | MEDP | DHR |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |